Combined pulmonary fibrosis and emphysema (CPFE) is a condition that causes symptoms of both pulmonary fibrosis and emphysema.
People with CPFE have both air sac destruction (seen in people with emphysema) and also scarred lung tissue of what holds the air sacs together (as seen with pulmonary fibrosis). CPFE is considered rare and — until recently — has usually been treated as two separate conditions.
CPFE is heavily linked to smoking, although environmental and genetic factors might also increase the risk. The only cure for CPFE is a lung transplant, but treatments such as inhaled corticosteroids and bronchodilators can improve symptoms in selected patients can help control chronic symptoms.
Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.
